Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility

  • Bioorg Med Chem Lett. 2001 Mar 26;11(6):803-7. doi: 10.1016/s0960-894x(01)00059-2.
A Guzman-Perez  1 ,  R T Wester ,  M C Allen ,  J A Brown ,  A R Buchholz ,  E R Cook ,  W W Day ,  E S Hamanaka ,  S P Kennedy ,  D R Knight ,  P J Kowalczyk ,  R B Marala ,  C J Mularski ,  W A Novomisle ,  R B Ruggeri ,  W R Tracey ,  R J Hill
Affiliations
  • 1. Pfizer Global Research and Development, Pfizer Inc., Groton CT 06340, USA. [email protected]
PMID: 11277524 DOI: 10.1016/s0960-894x(01)00059-2
Abstract

Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aqueous solubility and acceptable pharmacokinetics for intravenous administration. The discovery, synthesis, activities, and rat and dog pharmacokinetics of this compound are presented. The potency and selectivity of zoniporide may be due to the conformation that the molecule adopts due to the presence of a cyclopropyl and a 5-quinolinyl substituent on the central pyrazole ring of the molecule.

Products